Bladder Cancer Treatment Market: By Cancer Type, By Drug Class, By Distribution Channel and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Bladder Cancer Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Cancer Type (Transitional Cell Bladder Cancer, Invasive Bladder Cancer, Superficial Bladder Cancer, Squamous Cell Bladder Cancer, Other Rare Types), By Drug Class (Chemotherapy And Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Bladder Cancer Treatment Market size was valued at 3.6 billion in 2023 and is expected to reach 4.8 billion by 2030, at a CAGR of 4.3% from 2024 to 2030. Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination, and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. As per the National Institute of Health, approximately 17,000 women and 45,000 men every year are diagnosed with bladder cancer in the U.S. only. The market for bladder cancer is rapidly increasing and it is anticipated to grow rapidly from 2016 to 2022 globally.

According to The American Cancer Society, in 2017, estimated bladder cancers in the United States 79,030 new cases (about 60,490 in men and 18,540 in women) were diagnosed, and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women). Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer treatment drugs. An increasing number of mergers and acquisitions, the rise in the number of collaborations and partnerships, new product launches, and growing awareness about the availability of bladder cancer treatment drugs are some of the latest trends that have been observed in the market.

summary download arrow Download Free Sample

Global Bladder Cancer Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.3%

Largest Market

North America

Fastest Growing Market

Asia-Pacific

Bladder Cancer Treatment Market Dynamics

Increase in incidence rate of bladder cancer cases, technological advancements, drug innovations with regard to the treatment of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer treatment drugs. In addition, the rise in awareness about bladder diseases, their available therapies in the market, and increase in health care expenditure are driving the global market for bladder cancer treatment drugs. However, the rise in a number of patent expirations, asymptomatic nature of the disease, and rise in the use of generic drugs are some of the major factors restraining the revenue growth of the global bladder cancer treatment drugs market over the forecast period.

Global Bladder Cancer Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market CAGR

4.3%

By Cancer Type

  • Transitional cell bladder cancer
  • Invasive bladder cancer
  • Superficial bladder cancer
  • Squamous cell bladder cancer
  • Other rare types

By Drug Class

  • Chemotherapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The bladder cancer treatment market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis 

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The bladder cancer treatment market size was valued at US$ 6,301.6 million in 2023 and is poised to grow at a significant CAGR of 4.7% from 2024-2030.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The key players of the market are AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc.( U.S.), Sanofi (France)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Bladder Cancer Treatment Market Introduction 
2.1.Global Bladder Cancer Treatment Market  - Taxonomy
2.2.Global Bladder Cancer Treatment Market  - Definitions
2.2.1.Cancer Type
2.2.2.Drug Class
2.2.3.Distribution Channel
2.2.4.Region
3.Global Bladder Cancer Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Bladder Cancer Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Bladder Cancer Treatment Market  By Cancer Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Transitional cell bladder cancer
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Invasive bladder cancer
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Superficial bladder cancer
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Squamous cell bladder cancer
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Other rare types
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Bladder Cancer Treatment Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Chemotherapy
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Immunotherapy
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Bladder Cancer Treatment Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Bladder Cancer Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Bladder Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Transitional cell bladder cancer
9.1.2.Invasive bladder cancer
9.1.3.Superficial bladder cancer
9.1.4.Squamous cell bladder cancer
9.1.5.Other rare types
9.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Chemotherapy
9.2.2.Immunotherapy
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Bladder Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Cancer Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Transitional cell bladder cancer
10.1.2.Invasive bladder cancer
10.1.3.Superficial bladder cancer
10.1.4.Squamous cell bladder cancer
10.1.5.Other rare types
10.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Chemotherapy
10.2.2.Immunotherapy
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Bladder Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Cancer Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Transitional cell bladder cancer
11.1.2.Invasive bladder cancer
11.1.3.Superficial bladder cancer
11.1.4.Squamous cell bladder cancer
11.1.5.Other rare types
11.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Chemotherapy
11.2.2.Immunotherapy
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Bladder Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Cancer Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Transitional cell bladder cancer
12.1.2.Invasive bladder cancer
12.1.3.Superficial bladder cancer
12.1.4.Squamous cell bladder cancer
12.1.5.Other rare types
12.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Chemotherapy
12.2.2.Immunotherapy
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Bladder Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Cancer Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Transitional cell bladder cancer
13.1.2.Invasive bladder cancer
13.1.3.Superficial bladder cancer
13.1.4.Squamous cell bladder cancer
13.1.5.Other rare types
13.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Chemotherapy
13.2.2.Immunotherapy
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.AstraZeneca plc (U.K.)
14.2.2.Bristol-Myers Squibb (U.S.)
14.2.3.Celgene Corporation (U.S.)
14.2.4.Eli Lilly and Company (U.S.)
14.2.5.F. Hoffmann-La Roche (Switzerland)
14.2.6.GlaxoSmithKline plc (U.K.)
14.2.7.Novartis AG (Switzerland)
14.2.8.Pfizer Inc.( U.S.)
14.2.9.Sanofi (France)
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • AstraZeneca plc (U.K.)
  • Bristol-Myers Squibb (U.S.)
  • Celgene Corporation (U.S.)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Pfizer Inc.( U.S.)
  • Sanofi (France)

Related Industry Reports

Blood Pressure Monitoring Devices Market

Blood Processing Devices And Consumables Market

Global Blood Grouping Reagents Market

Global Breast Cancer Treatment Market